AGAP2 and central nervous system cancer: Additionally, AGAP2-AS1 exhibits high expression in gliomas, where it may function as an oncogene by inhibiting the expression of miR-497-5p, thus highlighting its potential as a prognostic biomarker and therapeutic target in gliomas [16].